Low risk prostate cancer in men ≥ 70 years old: To treat or not to treat

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 6, 2013, Pages 755-760

  Rice, Kevin R ^a   Colombo, Monica L ^a   Wingate, Jonathan ^a   Chen, Yongmei ^b   Cullen, Jennifer ^b   McLeod, David G ^a,b   Brassell, Stephen A ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Center for Prostate Disease Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CRYOTHERAPY; ETHNICITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; WATCHFUL WAITING;

AGE; CANCER SCREENING; LOW RISK; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84880699800     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.07.004     Document Type: Article

References (24)

1. Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60: 277-300.
2. Jemal A., Center M.M., DeSantis C., et al. Global patterns of cancer incidence and mortality rates and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19: 1893-1907.
3. Prostate Cancer National Institute of Health, Accessed 16 Mar 2011. http://www.cancer.gov/cancertopics/types/prostate.
4. Scherr D., Swindle P.W., Scardino P.T. National Comprehensive Cancer Network of Guidelines for the Management of Prostate Cancer. Urology 2003, 61(2 Suppl 1): 14-24.
5. Sun L., Caire A.A., Robertson C.N., et al. Men older than 70 years have higher risk of prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009, 182: 2242-2248.
6. Konety B.R., Cowan J.E., Carroll P.R. Patterns of primary and secondary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE. J Urol 2008, 179: 1797-1803. CaPSURE Investigators.
7. Brassell S.A., Rice K.R., Parker P.M., et al. Prostate cancer in men 70 years old or older, indolent or aggressive: Clinicopathologic analysis and outcomes. J Urol 2011, 185: 132-137.
8. Dahm P., Silverstein A.D., Weizer A.Z., et al. When to diagnose and how to treat prostate cancer in the "not too fit" elderly. Crit Rev Oncol Hematol 2003, 48: 123-131.
9. Nguyen P.L., Chen M., Renshaw A.A., et al. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: Implications for screening recommendations. Int J Radiat Oncol Biol Phys 2010, 76: 337-341.
10. Pierorazio P.M., Humphreys E., Walsh P.C., et al. Radical prostatectomy in older men: Survival outcomes in septuagenarians and octogenarians. BJU Int 2010, 106: 791-795.
11. Tewari A., Raman J.D., Chang P., et al. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). J Urol 2006, 68: 1268-1274.
12. Namiki S., Ishidoya S., Kawamura S., et al. Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. J Cancer Res Clin Oncol 2010, 136: 379-386.
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280: 969-974.
14. Tseng K.S., Landis P., Epstein J.I., et al. Risk Stratification of Men Choosing Active Surveillance for Low Risk Prostate Cancer. J Urol 2010, 183: 1779-1785.
15. Lin K., Lipsitz R., Miller T., et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008, 149: 192-199. U.S. Preventative Service Task Force.
16. Greene K.L., Albertsen P.C., Babaian R.J., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009, 182: 2232-2241.
17. Mohler J., Bahnson R.R., Boston B., et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010, 8: 162-200.
18. SEER Cancer Statistics Review, 1975-2007 Accessed 30 Jan 2011. http://seer.cancer.gov/statfacts/html/prost.html.
19. Bechis S.K., Carroll P.C., Cooperberg M.R. Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. J Clin Oncol 2010, 29: 235-241.
20. Abdollah F., Sun M., Thuret R., et al. A Competing-Risks Analysis of Survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011, 59: 88-95.
21. Droz J.P., Balducci L., Bolla M., et al. Management of prostate cancer in older men: Recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010, 106: 462-469.
22. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy vs. watchful waiting in early prostate cancer. N Engl J Med 2011, 364: 1708-1717.
23. Van den Bergh R.C., Steyerberg E.W., Khatami A., et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?. Cancer 2010, 116: 1281-1290.
24. Dall'era M.A., Cowan J.E., Simko J., et al. Surgical management after active surveillance for low-risk prostate cancer: Pathologic outcomes compared with men undergoing immediate treatment. BJU Int 2010 Aug 26, [Epub ahead of print].